{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T18:46:57Z","timestamp":1789498017214,"version":"build-2803163510"},"reference-count":61,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2023,8,27]],"date-time":"2023-08-27T00:00:00Z","timestamp":1693094400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R44CA199767"],"award-info":[{"award-number":["R44CA199767"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA197792"],"award-info":[{"award-number":["R01CA197792"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R21CA234701"],"award-info":[{"award-number":["R21CA234701"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R56HL155582"],"award-info":[{"award-number":["R56HL155582"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Multiple myeloma (MM) is a common hematological malignancy that has fostered several new therapeutic approaches to combat newly diagnosed or relapsed MM. While the field has advanced over the past 2 decades, the majority of patients will develop resistance to these treatments, causing the need for new therapeutic targets. SLAMF7 is an attractive therapeutic target in multiple myeloma, and a monoclonal antibody that targets SLAMF7 has shown consistent beneficial outcomes in clinical trials to date. In this review, we will focus on the structure and regulation of SLAMF7 and its mechanism of action. The most recent clinical trials will be reviewed to further understand the clinical implications and improve the prognosis of MM. Furthermore, the efficacy of anti-SLAMF7 monoclonal antibodies combined with standard therapies and possible resistance mechanisms will be discussed. This review aimed to provide a detailed summary of the role of SLAMF7 in the pathogenesis of patients with MM and the rationale for further investigation into SLAMF7-mediated molecular pathways associated with MM development.<\/jats:p>","DOI":"10.3390\/curroncol30090573","type":"journal-article","created":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T06:57:35Z","timestamp":1693205855000},"page":"7891-7903","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["SLAMF7 as a Promising Immunotherapeutic Target in Multiple Myeloma Treatments"],"prefix":"10.3390","volume":"30","author":[{"given":"Emily","family":"Chu","sequence":"first","affiliation":[{"name":"Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA"},{"name":"Trinity College of Arts and Sciences, Duke University, Durham, NC 27708, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7065-9917","authenticated-orcid":false,"given":"Jian","family":"Wu","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey S.","family":"Kang","sequence":"additional","affiliation":[{"name":"College of Arts and Sciences, Washington University in St. Louis, St. Louis, MO 63130, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yubin","family":"Kang","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,8,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.2215\/CJN.03060906","article-title":"Multiple Myeloma","volume":"1","author":"Singhal","year":"2006","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_3","unstructured":"Albagoush, S.A., Shumway, C., and Azevedo, A.M. (2023). Multiple Myeloma, StatPearls Publishing LLC."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.imbio.2015.08.005","article-title":"Blimp-1\/PRDM1 regulates the transcription of human CS1 (SLAMF7) gene in NK and B cells","volume":"221","author":"Kim","year":"2016","journal-title":"Immunobiology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/cts.12532","article-title":"Mechanisms of Action and Clinical Development of Elotuzumab","volume":"11","author":"Ritchie","year":"2018","journal-title":"Clin. Transl. Sci."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.3389\/fimmu.2018.02551","article-title":"Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma","volume":"9","author":"Campbell","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3088","DOI":"10.1038\/s41375-020-0860-7","article-title":"Soluble SLAMF7 is a predictive biomarker for elotuzumab therapy","volume":"34","author":"Suzuki","year":"2020","journal-title":"Leukemia"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1038\/s41375-022-01559-4","article-title":"CS1 CAR-T targeting the distal domain of CS1 (SLAMF7) shows efficacy in high tumor burden myeloma model despite fratricide of CD8+CS1 expressing CAR-T cells","volume":"36","author":"Ritchey","year":"2022","journal-title":"Leukemia"},{"key":"ref_9","first-page":"4721","article-title":"Deglycosylation of SLAMF7 in breast cancers enhances phagocytosis","volume":"12","author":"Wang","year":"2022","journal-title":"Am. J. Cancer Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1002\/eji.200424917","article-title":"Molecular and functional characterization of a CS1 (CRACC) splice variant expressed in human NK cells that does not contain immunoreceptor tyrosine-based switch motifs","volume":"34","author":"Lee","year":"2004","journal-title":"Eur. J. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Buller, C.W., Mathew, P.A., and Mathew, S.O. (2020). Roles of NK Cell Receptors 2B4 (CD244), CS1 (CD319), and LLT1 (CLEC2D) in Cancer. Cancers, 12.","DOI":"10.3390\/cancers12071755"},{"key":"ref_12","first-page":"1637","article-title":"CS1 (SLAMF7, CD319) is an effective immunotherapeutic target for multiple myeloma","volume":"7","author":"Malaer","year":"2017","journal-title":"Am. J. Cancer Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.molimm.2012.12.017","article-title":"YY1 and a unique DNA repeat element regulates the transcription of mouse CS1 (CD319, SLAMF7) gene","volume":"54","author":"Dongre","year":"2013","journal-title":"Mol. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/sj.gene.6364453","article-title":"Association of LY9 in UK and Canadian SLE families","volume":"9","author":"Graham","year":"2008","journal-title":"Genes. Immun."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.exphem.2020.08.006","article-title":"The SLAMF3 rs509749 polymorphism correlates with malignant potential in multiple myeloma","volume":"90","author":"Ishibashi","year":"2020","journal-title":"Exp. Hematol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2008-04-147884","article-title":"Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: A genome-wide single nucleotide polymorphism analysis","volume":"112","author":"Sarasquete","year":"2008","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"67","DOI":"10.21873\/anticanres.13080","article-title":"A Single Nucleotide Polymorphism in SLC7A5 Was Associated With Clinical Response in Multiple Myeloma Patients","volume":"39","author":"Poi","year":"2019","journal-title":"Anticancer. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s10238-020-00681-w","article-title":"IDO2 rs10109853 polymorphism affects the susceptibility to multiple myeloma","volume":"21","author":"Kasamatsu","year":"2021","journal-title":"Clin. Exp. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/leu.2012.232","article-title":"Single-nucleotide polymorphism rs1052501 associated with monoclonal gammopathy of undetermined significance and multiple myeloma","volume":"27","author":"Greenberg","year":"2013","journal-title":"Leukemia"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s00280-017-3481-8","article-title":"Pharmacogenetic study of the impact of ABCB1 single-nucleotide polymorphisms on lenalidomide treatment outcomes in patients with multiple myeloma: Results from a phase IV observational study and subsequent phase II clinical trial","volume":"81","author":"Lund","year":"2018","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1016\/j.celrep.2017.08.062","article-title":"Genetic Predisposition to Multiple Myeloma at 5q15 Is Mediated by an ELL2 Enhancer Polymorphism","volume":"20","author":"Li","year":"2017","journal-title":"Cell Rep."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/s41408-021-00468-6","article-title":"Germline variants at SOHLH2 influence multiple myeloma risk","volume":"11","author":"Thorleifsson","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.3109\/10428194.2015.1099648","article-title":"Single nucleotide polymorphisms in TP53 but not KRAS or MDM2 are predictive of clinical outcome in multiple myeloma treated with high-dose melphalan and autologous stem cell support","volume":"57","author":"Gebauer","year":"2016","journal-title":"Leuk. Lymphoma"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/ng.2583","article-title":"The CCND1 c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma","volume":"45","author":"Weinhold","year":"2013","journal-title":"Nat. Genet."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1007\/s00277-011-1194-3","article-title":"Single nucleotide polymorphisms in the promoter region of the IL1B gene influence outcome in multiple myeloma patients treated with high-dose chemotherapy independently of relapse treatment with thalidomide and bortezomib","volume":"90","author":"Vangsted","year":"2011","journal-title":"Ann. Hematol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"34784","DOI":"10.18632\/oncotarget.26196","article-title":"Clinical impact of serum soluble SLAMF7 in multiple myeloma","volume":"9","author":"Ishibashi","year":"2018","journal-title":"Oncotarget"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1038\/s41375-021-01172-x","article-title":"Selective elimination of immunosuppressive T cells in patients with multiple myeloma","volume":"35","author":"Awwad","year":"2021","journal-title":"Leukemia"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/s12974-022-02594-9","article-title":"SLAMF7 modulates B cells and adaptive immunity to regulate susceptibility to CNS autoimmunity","volume":"19","author":"Blake","year":"2022","journal-title":"J. Neuroinflammation"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nature22076","article-title":"SLAMF7 is critical for phagocytosis of haematopoietic tumour cells via Mac-1 integrin","volume":"544","author":"Chen","year":"2017","journal-title":"Nature"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"eabf2846","DOI":"10.1126\/sciimmunol.abf2846","article-title":"SLAMF7 engagement superactivates macrophages in acute and chronic inflammation","volume":"7","author":"Simmons","year":"2022","journal-title":"Sci. Immunol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e150224","DOI":"10.1172\/JCI150224","article-title":"SLAMF7 regulates the inflammatory response in macrophages during polymicrobial sepsis","volume":"133","author":"Wu","year":"2023","journal-title":"J. Clin. Investig."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/eji.202149406","article-title":"SLAMF7 selectively favors degranulation to promote cytotoxicity in human NK cells","volume":"52","author":"Veillette","year":"2022","journal-title":"Eur. J. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e1339853","DOI":"10.1080\/2162402X.2017.1339853","article-title":"The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and -independent mechanisms","volume":"6","author":"Pazina","year":"2017","journal-title":"Oncoimmunology"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"193","DOI":"10.4049\/jimmunol.2000300","article-title":"SLAMF7 Signaling Reprograms T Cells toward Exhaustion in the Tumor Microenvironment","volume":"206","author":"Hyslop","year":"2021","journal-title":"J. Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"8975","DOI":"10.3390\/curroncol29110705","article-title":"Treating Multiple Myeloma in the Context of the Bone Marrow Microenvironment","volume":"29","author":"Ho","year":"2022","journal-title":"Curr. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Cho, S.-F., Xing, L., Anderson, K.C., and Tai, Y.-T. (2021). Promising Antigens for the New Frontier of Targeted Immunotherapy in Multiple Myeloma. Cancers, 13.","DOI":"10.3390\/cancers13236136"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1182\/blood-2016-01-691162","article-title":"APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment","volume":"127","author":"Tai","year":"2016","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1182\/blood-2007-08-107292","article-title":"Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu","volume":"112","author":"Tai","year":"2008","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13045-016-0284-z","article-title":"Elotuzumab for the treatment of multiple myeloma","volume":"9","author":"Wang","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/s41375-019-0525-6","article-title":"Soluble SLAMF7 promotes the growth of myeloma cells via homophilic interaction with surface SLAMF7","volume":"34","author":"Kikuchi","year":"2020","journal-title":"Leukemia"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1080\/17474086.2018.1456331","article-title":"Anti-CD38 and anti-SLAMF7: The future of myeloma immunotherapy","volume":"11","author":"Zamagni","year":"2018","journal-title":"Expert. Rev. Hematol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s40262-017-0585-6","article-title":"The Clinical Pharmacology of Elotuzumab","volume":"57","author":"Passey","year":"2018","journal-title":"Clin. Pharmacokinet."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1158\/2326-6066.CIR-18-0579","article-title":"Enhanced SLAMF7 Homotypic Interactions by Elotuzumab Improves NK Cell Killing of Multiple Myeloma","volume":"7","author":"Pazina","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e2018014","DOI":"10.4084\/mjhid.2018.014","article-title":"Elotuzumab for the Treatment of Relapsed or Refractory Multiple Myeloma, with Special Reference to its Modes of Action and SLAMF7 Signaling","volume":"10","author":"Taniwaki","year":"2018","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1177\/2040620716657993","article-title":"Treatment of multiple myeloma with the immunostimulatory SLAMF7 antibody elotuzumab","volume":"7","author":"Einsele","year":"2016","journal-title":"Ther. Adv. Hematol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1182\/blood-2011-06-360552","article-title":"A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma","volume":"120","author":"Zonder","year":"2012","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e403","DOI":"10.1016\/S2352-3026(22)00103-X","article-title":"Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): An open-label, multicentre, randomised, phase 3 trial","volume":"9","author":"Dimopoulos","year":"2022","journal-title":"Lancet Haematol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMoa1805762","article-title":"Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma","volume":"379","author":"Dimopoulos","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1200\/JCO.21.02815","article-title":"Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed\/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial","volume":"41","author":"Dimopoulos","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1182\/blood-2019-130277","article-title":"A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)","volume":"134","author":"Berdeja","year":"2019","journal-title":"Blood"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1182\/blood.V126.23.510.510","article-title":"Elotuzumab Plus Bortezomib and Dexamethasone Versus Bortezomib and Dexamethasone in Patients with Relapsed\/Refractory Multiple Myeloma: 2-Year Follow-up","volume":"126","author":"Palumbo","year":"2015","journal-title":"Blood"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1182\/blood-2020-138447","article-title":"Carfilzomib, Elotuzumab and Dexamethasone for Relapsed or Refractory Myeloma Patients","volume":"136","author":"Silvennoinen","year":"2020","journal-title":"Blood"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"8011","DOI":"10.1200\/JCO.2021.39.15_suppl.8011","article-title":"Interim analysis of a phase 2 minimal residual disease (MRD)-adaptive trial of elotuzumab, carfilzomib, lenalidomide, and dexamethasone (Elo-KRd) for newly diagnosed multiple myeloma (MM)","volume":"39","author":"Derman","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1182\/blood-2017-04-778423","article-title":"SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7+ normal lymphocytes","volume":"130","author":"Gogishvili","year":"2017","journal-title":"Blood"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e446","DOI":"10.1016\/S2352-3026(21)00057-0","article-title":"CAR T-cell therapy for multiple myeloma: State of the art and prospects","volume":"8","author":"Usmani","year":"2021","journal-title":"Lancet Haematol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.3389\/fonc.2020.01243","article-title":"CAR T-Cells in Multiple Myeloma: State of the Art and Future Directions","volume":"10","author":"Ganzetti","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.ymthe.2020.10.008","article-title":"Development of CAR T Cells Expressing a Suicide Gene Plus a Chimeric Antigen Receptor Targeting Signaling Lymphocytic-Activation Molecule F7","volume":"29","author":"Amatya","year":"2021","journal-title":"Mol. Ther."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/s41434-021-00254-w","article-title":"CARAMBA: A first-in-human clinical trial with SLAMF7 CAR-T cells prepared by virus-free Sleeping Beauty gene transfer to treat multiple myeloma","volume":"28","author":"Prommersberger","year":"2021","journal-title":"Gene Ther."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41408-021-00469-5","article-title":"CAR T-cell therapy in multiple myeloma: More room for improvement","volume":"11","author":"Teoh","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Davis, L.N., and Sherbenou, D.W. (2021). Emerging Therapeutic Strategies to Overcome Drug Resistance in Multiple Myeloma. Cancers, 13.","DOI":"10.3390\/cancers13071686"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/30\/9\/573\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:40:07Z","timestamp":1760128807000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/30\/9\/573"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,27]]},"references-count":61,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["curroncol30090573"],"URL":"https:\/\/doi.org\/10.3390\/curroncol30090573","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,27]]}}}